All PlansCoverageMedium impact
Laboratory Tests for Organ Transplant Rejection
Regence BlueShield·Cardiothoracic Surgery, Transplant Surgery, Cardiology +1 more·Laboratory & Genetics
Effective date
Sep 1, 2026
We identified it
Sep 2, 2026
Summary
This new policy (effective September 1, 2026) establishes coverage criteria for laboratory tests used to detect organ transplant rejection. Only peripheral blood gene expression profiling tests (e.g., AlloMap) for heart transplant patients meeting specific criteria are covered as medically necessary; all other transplant rejection tests—including donor-derived cell-free DNA, volatile organic compounds, and tissue-based gene expression tests—are classified as investigational and not covered.
Action Required
By September 1, 2026: Billing team must implement claims review procedures to verify that heart transplant rejection laboratory tests meet ALL four criteria (patient age ≥15 years, ≥2 months post-transplant, no documented rejection signs/symptoms, no history of rejection treatment) before processing claims as medically necessary. Providers must submit clinical documentation including test name, billing codes, history/physical exam, and transplant date with all claims. Deny or request prior authorization for any rejection tests on non-heart organs or tests listed as investigational (donor-derived cell-free DNA, AlloSure, Prospera, HeartCare combination tests, volatile organic compound tests, tissue-based Molecular Microscope, urinary CXCL10/IP-10, and non-HLA autoantibody tests). Update billing system with investigational test codes to auto-flag for denial. Educate providers that patients may be billed for investigational services if they are informed beforehand.